Inside ASH 2025: What’s New for MPN (Polycythemia Vera, Essential Thrombocythemia and Myelofibrosis) Patients with Dr. Claire Harrison

Dalton joined HealthTree in 2024 as the MPNs and MDS Program Manager. He is passionate about helping patients gain a better understanding of their health and treatment and sees it as a way to help empower individuals and their families who are affected by these diseases. Prior to joining HealthTree Dalton earned a Master’s Degree in Oncological Sciences while studying various different blood cancers. When not interacting with patients he is an avid snowboarder and hiker.

Professor Claire Harrison graduated from Oxford Univeristy Medical School and became a consultant at the Guy’s and St Thomas Hospital in 2001, where she is now a deputy chief medical officer. The focus of her clinical work is myeloproliferative neoplasms (MPN), for which she has a national and international reputation. Key areas of interest are clinical trials and associated translational research. Her work has led to the approval of new therapies such a ruxolitinib, fedratinib, momelotinib and pacritinib. In the past 10 years she has published widely (>300 academic articles). In addition she has a strong interest in patient advocacy and founded the UK MPN group www.mpnvoice.org.uk.